WASHINGTON, July 12, 2023 /PRNewswire/ -- Current Surgical Inc., a medical technology company developing a new surgical platform to improve the safety and efficacy of cancer surgery, today announced that it has received a $400,000 grant from the National Institutes of Health (NIH) to support the development of its technology. The grant, awarded by the NIH's National Cancer Institute (NCI), will be used to develop and validate the company's technology in a preclinical setting.Cancer continues to be a leading cause of death worldwide, with more than 18 million new cases detected every year. Even though more than 50 percent of these cases are now detected at an early stage, curative options have not kept pace.Current Surgical has set out to change that. Their smart surgical needle technology combines high resolution sensors and real-time image analysis into one tool, giving doctors precise control and feedback while destroying tumors. As a result, surgeons will be able to treat any solid tumor in any location — allowing millions of patients to receive curative surgery without the traditional limitations."We are excited to receive this funding from the NCI," said Al Mashal, CEO of Current Surgical. "This grant will allow us to accelerate the development of our platform and bring it to patients as soon as possible.""Our technology has the potential to make a significant impact on the way cancer surgery is performed," said Chris Wagner, CTO of Current Surgical

Current Surgical Inc., a medical technology company developing a new surgical platform to improve the safety and efficacy of cancer surgery, today announced that it has received a $400,000 grant from the National Institutes of Health (NIH) to support the development of its technology.